Drugs / Tritanrix-HepB/Hib™
last change Apr 2008 re-read 2 minutes ago

Tritanrix-HepB/Hib™

Vaccine

Developed for
diphtheria · haemophilus infectious disease · hepatitis B virus infection · pertussis · tetanus

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00343889 Comparator Aug 2006 → Nov 2007 diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Tritanrix-HepB/Hib ClinicalTrials.gov intervention name — accepted as the source's own label NCT00343889
Modality Vaccine “Tritanrix-HepB/Hib™ + OPV vaccineNCT00343889
Route Intramuscular “0.5 mL, IntramuscularNCT00343889